Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1998;98:2574-2579

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deedwania, P. C.
Right arrow Articles by Singh, S. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deedwania, P. C.
Right arrow Articles by Singh, S. N.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*AMIODARONE HYDROCHLORIDE
Medline Plus Health Information
*Heart Failure

(Circulation. 1998;98:2574-2579.)
© 1998 American Heart Association, Inc.


Clinical Investigation and Reports

Spontaneous Conversion and Maintenance of Sinus Rhythm by Amiodarone in Patients With Heart Failure and Atrial Fibrillation

Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT)

Prakash C. Deedwania, MD; Bramah N. Singh, MD, PhD; Kenneth Ellenbogen, MD; Susan Fisher, PhD; Ross Fletcher, MD; Steven N. Singh, MD; for the Department of Veterans Affairs CHF-STAT Investigators

From University of California, San Francisco School of Medicine, Fresno, Calif (P.C.D.); Stanford University, Stanford, Calif (P.C.D.); Veterans Affairs Medical Center, Fresno (P.C.D.), Los Angeles (B.N.S.), Richmond (K.E.), and Washington, DC (S.N.S., R.F.); Medical College of Virginia, Richmond (K.E.), and Cooperative Studies Program, Hines, Ill (S.F.).

Correspondence to Prakash C. Deedwania, MD, Cardiology Section, VAMC/UCSF Program, 2615 East Clinton Avenue, Fresno, CA 93703. E-mail deed{at}ucsfresno.edu

Background—In a multicenter, double-blind, placebo-controlled study, the long-term effects of amiodarone on morbidity and mortality in patients with congestive heart failure (CHF) and atrial fibrillation (AF) were evaluated during a 4-year period.

Methods and Results—Of 667 patients with CHF, 103 (15%) had AF at baseline. Of these, 51 were randomized to amiodarone and 52 to placebo. The group with sinus rhythm and the group in AF were comparable except for a higher proportion of AF in patients with nonischemic versus ischemic cardiomyopathy (41% versus 27%, P<0.005). The mean ventricular response (VR) during AF over 24 hours was reduced by amiodarone at 2 weeks (20%, P=0.001), at 6 months (18%, P=0.001), and at 12 months (16%, P=0.006). Maximal VR was reduced 22% (P=0.001) at 2 weeks, 19% (P=0.001) at 6 months, and 14% (P=0.001) at 12 months. Sixteen of 51 patients on amiodarone and 4 of 52 on placebo converted to sinus rhythm during the study ({chi}2=9.23, P=0.002). During follow-up, 11 of 268 patients in sinus rhythm on amiodarone at baseline and 22 of the 263 in sinus rhythm on placebo developed AF; the difference was significant ({chi}2=12.88, P=0.005). Analysis of total mortality during follow-up showed a significantly lower mortality rate (P=0.04) in patients in AF at baseline who subsequently converted to sinus rhythm on amiodarone than in those who did not convert to sinus rhythm on the drug.

Conclusions—In patients with CHF, amiodarone has a significant potential to spontaneously convert patients in AF to sinus rhythm, with patients who convert having a lower mortality rate than those who do not. The drug prevented the development of new-onset AF and significantly reduced the VR in those with persistent AF.


Key Words: fibrillation, atrial • heart failure • drugs • survival




This article has been cited by other articles:


Home page
NEJMHome page
D. Roy, M. Talajic, S. Nattel, D. G. Wyse, P. Dorian, K. L. Lee, M. G. Bourassa, J. M. O. Arnold, A. E. Buxton, A. J. Camm, et al.
Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure
N. Engl. J. Med., June 19, 2008; 358(25): 2667 - 2677.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
H.-R. Neuberger, C. Mewis, D. J. van Veldhuisen, U. Schotten, I. C. van Gelder, M. A. Allessie, and M. Bohm
Management of atrial fibrillation in patients with heart failure
Eur. Heart J., November 1, 2007; 28(21): 2568 - 2577.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
P. Vassallo and R. G. Trohman
Prescribing Amiodarone: An Evidence-Based Review of Clinical Indications
JAMA, September 19, 2007; 298(11): 1312 - 1322.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
B. N. Singh and E. Aliot
Newer antiarrhythmic agents for maintaining sinus rhythm in atrial fibrillation: simplicity or complexity?
Eur. Heart J. Suppl., September 1, 2007; 9(suppl_G): G17 - G25.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
I. C. Van Gelder and M. E.W. Hemels
The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm
Europace, November 1, 2006; 8(11): 943 - 949.
[Abstract] [Full Text] [PDF]


Home page
EuropaceHome page
Writing Committee Members, V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, et al.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
Europace, September 1, 2006; 8(9): 651 - 745.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
J. Am. Coll. Cardiol., August 15, 2006; 48(4): e149 - e246.
[Full Text] [PDF]


Home page
CirculationHome page
V. Fuster, L. E. Ryden, D. S. Cannom, H. J. Crijns, A. B. Curtis, K. A. Ellenbogen, J. L. Halperin, J.-Y. Le Heuzey, G. N. Kay, J. E. Lowe, et al.
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society
Circulation, August 15, 2006; 114(7): e257 - e354.
[Full Text] [PDF]


Home page
Eur Heart JHome page
A. A. Elesber, A. G. Rosales, R. M. Herges, W.-K. Shen, B. S. Moon, J. F. Malouf, N. M. Ammash, V. Somers, D. O. Hodge, B. J. Gersh, et al.
Relapse and mortality following cardioversion of new-onset vs. recurrent atrial fibrillation and atrial flutter in the elderly
Eur. Heart J., April 1, 2006; 27(7): 854 - 860.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
B. N. Singh
{beta}-Adrenergic Blockers as Antiarrhythmic and Antifibrillatory Compounds: An Overview
Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S3 - S14.
[Abstract] [PDF]


Home page
CirculationHome page
A. Verma, A. Natale, B. J. Padanilam, E. N. Prystowsky, A. Verma, A. Natale, B. J. Padanilam, and E. N. Prystowsky
Why Atrial Fibrillation Ablation Should Be Considered First-Line Therapy for Some Patients
Circulation, August 23, 2005; 112(8): 1214 - 1222.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. H.K. Vogel, S. F. Bolling, R. B. Costello, E. M. Guarneri, M. W. Krucoff, J. C. Longhurst, B. Olshansky, K. R. Pelletier, C. M. Tracy, R. A. Vogel, et al.
Integrating Complementary Medicine Into Cardiovascular Medicine: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine)
J. Am. Coll. Cardiol., July 5, 2005; 46(1): 184 - 221.
[Full Text] [PDF]


Home page
Eur Heart JHome page
K. Swedberg, L. G. Olsson, A. Charlesworth, J. Cleland, P. Hanrath, M. Komajda, M. Metra, C. Torp-Pedersen, and P. Poole-Wilson
Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET
Eur. Heart J., July 1, 2005; 26(13): 1303 - 1308.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
P. Zimetbaum
An Argument for Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
Circulation, June 14, 2005; 111(23): 3150 - 3156.
[Full Text] [PDF]


Home page
NEJMHome page
B. N. Singh, S. N. Singh, D. J. Reda, X. C. Tang, B. Lopez, C. L. Harris, R. D. Fletcher, S. C. Sharma, J. E. Atwood, A. K. Jacobson, et al.
Amiodarone versus Sotalol for Atrial Fibrillation
N. Engl. J. Med., May 5, 2005; 352(18): 1861 - 1872.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
M. Lehto, S. Snapinn, K. Dickstein, K. Swedberg, M. S. Nieminen, and on behalf of the OPTIMAAL investigators
Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience
Eur. Heart J., February 2, 2005; 26(4): 350 - 356.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
L.-F. Hsu, P. Jais, P. Sanders, S. Garrigue, M. Hocini, F. Sacher, Y. Takahashi, M. Rotter, J.-L. Pasquie, C. Scavee, et al.
Catheter Ablation for Atrial Fibrillation in Congestive Heart Failure
N. Engl. J. Med., December 2, 2004; 351(23): 2373 - 2383.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Y.-M. Cha, M. M. Redfield, W.-K. Shen, and B. J. Gersh
Atrial Fibrillation and Ventricular Dysfunction: A Vicious Electromechanical Cycle
Circulation, June 15, 2004; 109(23): 2839 - 2843.
[Full Text] [PDF]


Home page
EuropaceHome page
T. Deneke, T. Lawo, B. Gerritse, B. Lemke, and for the European GEM DRTM Investigators
Mortality of patients with implanted cardioverter/defibrillators in relation to episodes of atrial fibrillation
Europace, January 1, 2004; 6(2): 151 - 158.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
R. L. McNamara, L. J. Tamariz, J. B. Segal, and E. B. Bass
Management of Atrial Fibrillation: Review of the Evidence for the Role of Pharmacologic Therapy, Electrical Cardioversion, and Echocardiography
Ann Intern Med, December 16, 2003; 139(12): 1018 - 1033.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. U. Khand, A. C. Rankin, W. Martin, J. Taylor, I. Gemmell, and J. G. F. Cleland
Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?
J. Am. Coll. Cardiol., December 3, 2003; 42(11): 1944 - 1951.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. A. Tejan-Sie, R. D. Murray, I. W. Black, S. E. Jasper, C. Apperson-Hansen, J. Li, E. A. Lieber, R. A. Grimm, A. L. Klein, and ACUTE Investigators
Spontaneous conversion of patients with atrial fibrillation scheduled for electrical cardioversion: An ACUTE trial ancillary study
J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1638 - 1643.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
J. Galperin, M. V. Elizari, P. A. Chiale, R. T. Molina, R. Ledesma, A. O. Scapin, M. V. Blanco, R. Bonato, M. Lago, and Grupo de Estudio de Fibrilacion Auricular Con Amio
Pharmacologic Reversion of Persistent Atrial Fibrillation with Amiodarone Predicts Long-Term Sinus Rhythm Maintenance
Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2003; 8(3): 179 - 186.
[Abstract] [PDF]


Home page
Eur Heart J SupplHome page
A. Capucci and D. Aschieri
Antiarrhythmic drug therapy: what is certain and what is to come
Eur. Heart J. Suppl., September 1, 2003; 5(suppl_H): H8 - H18.
[Abstract] [PDF]


Home page
CirculationHome page
T. J. Wang, M. G. Larson, D. Levy, R. S. Vasan, E. P. Leip, P. A. Wolf, R. B. D'Agostino, J. M. Murabito, W. B. Kannel, and E. J. Benjamin
Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality: The Framingham Heart Study
Circulation, June 17, 2003; 107(23): 2920 - 2925.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
G. C. Gronefeld and S. H. Hohnloser
Heart Failure Complicated by Atrial Fibrillation: Mechanistic, Prognostic, and Therapeutic Implications
Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2003; 8(2): 107 - 113.
[Abstract] [PDF]


Home page
EuropaceHome page
I. Savelieva and A. John Camm
Atrial fibrillation and heart failure: natural history and pharmacological treatment
Europace, January 1, 2003; 5(s1): S5 - S19.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
Y Blaauw, I C Van Gelder, and H J G M Crijns
Treatment of atrial fibrillation
Heart, October 1, 2002; 88(4): 432 - 437.
[Full Text] [PDF]


Home page
Eur Heart JHome page
S.R. Raj and D.G. Wyse
Rhythm control for paroxysmal atrial fibrillation after AV junction ablation: is it worth the effort?
Eur. Heart J., June 1, 2002; 23(11): 845 - 848.
[Full Text] [PDF]


Home page
Eur Heart JHome page
M. Brignole, C. Menozzi, M. Gasparini, M. G. Bongiorni, G.L. Botto, R. Ometto, P. Alboni, C. Bruna, A. Vincenti, and R. Verlato
An evaluation of the strategy of maintenance of sinus rhythm by antiarrhythmic drug therapy after ablation and pacing therapy in patients with paroxysmal atrial fibrillation
Eur. Heart J., June 1, 2002; 23(11): 892 - 900.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
J. Galperin, M. V. Elizari, P. A. Chiale, R. T. Molina, R. Ledesma, A. O. Scapin, and M. V. Blanco
Efficacy of Amiodarone for the Termination of Chronic Atrial Fibrillation and Maintenance of Normal Sinus Rhythm: A Prospective, Multicenter, Randomized, Controlled, Double Blind Trial
Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2001; 6(4): 341 - 350.
[Abstract] [PDF]


Home page
Eur Heart JHome page
Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology
Eur. Heart J., October 2, 2001; 22(20): 1852 - 1923.
[PDF]


Home page
J Am Coll CardiolHome page
V. Fuster, L. E. Ryden, R. W. Asinger, D. S. Cannom, H. J. Crijns, R. L. Frye, J. L. Halperin, G. N. Kay, W. W. Klein, S. Levy, et al.
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology
J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1266 - 1266.
[Full Text] [PDF]


Home page
Eur Heart JHome page
J.G.F. Cleland, K. Thygesen, B.F. Uretsky, P. Armstrong, J.D. Horowitz, B. Massie, M. Packer, P.A. Poole-Wilson, L. Ryden, and on behalf of the ATLAS investigators
Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study
Eur. Heart J., September 1, 2001; 22(17): 1601 - 1612.
[Abstract] [PDF]


Home page
CirculationHome page
O. D. Pedersen, H. Bagger, N. Keller, B. Marchant, L. Kober, and C. Torp-Pedersen
Efficacy of Dofetilide in the Treatment of Atrial Fibrillation-Flutter in Patients With Reduced Left Ventricular Function: A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy
Circulation, July 17, 2001; 104(3): 292 - 296.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. Azpitarte, O. Baun, E. Moreno, R. Garcia-Orta, J. Sanchez-Ramos, and L. Tercedor
In Patients With Chronic Atrial Fibrillation and Left Ventricular Systolic Dysfunction, Restoration of Sinus Rhythm Confers Substantial Benefit
Chest, July 1, 2001; 120(1): 132 - 138.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A.U Khand, I Gemmell, A.C Rankin, and J.G.F Cleland
Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges
Eur. Heart J., January 2, 2001; 22(2): 153 - 164.
[Abstract] [PDF]


Home page
Eur Heart JHome page
H.J.G.M Crijns, G Tjeerdsma, P.J de Kam, F Boomsma, I.C van Gelder, M.P van den Berg, and D.J van Veldhuisen
Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure
Eur. Heart J., August 1, 2000; 21(15): 1238 - 1245.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
S.-H. Lee, C.-M. Chang, M.-J. Lu, R.-J. Lee, J.-J. Cheng, C.-R. Hung, and S.-A. Chen
Intravenous amiodarone for prevention of atrial fibrillation after coronary artery bypass grafting
Ann. Thorac. Surg., July 1, 2000; 70(1): 157 - 161.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A.U Khand, A.C Rankin, G.C Kaye, and J.G.F Cleland
Systematic review of the management of atrial fibrillation in patients with heart failure
Eur. Heart J., April 2, 2000; 21(8): 614 - 632.
[Abstract] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
S. H. Hohnloser, Y.-G. Li, B. Bender, and G. Gronefeld
Review : Pharmacological Management of Atrial Fibrillation: An Update
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(1): 11 - 16.
[Abstract] [PDF]


Home page
CirculationHome page
S. J. Connolly
Evidence-Based Analysis of Amiodarone Efficacy and Safety
Circulation, November 9, 1999; 100(19): 2025 - 2034.
[Full Text] [PDF]


Home page
Postgrad. Med. J.Home page
O M P JOLOBE;, Y. KREISS, Y. SIDI, and H. GUR
Amiodarone in atrial fibrillation
Postgrad. Med. J., November 1, 1999; 75(889): 703a - 703.
[Full Text]


Home page
NEJMHome page
C. Torp-Pedersen, M. Moller, P. E. Bloch-Thomsen, L. Kober, E. Sandoe, K. Egstrup, E. Agner, J. Carlsen, J. Videbak, B. Marchant, et al.
Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction
N. Engl. J. Med., September 16, 1999; 341(12): 857 - 865.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
W. G. Stevenson and L. W. Stevenson
Atrial Fibrillation in Heart Failure
N. Engl. J. Med., September 16, 1999; 341(12): 910 - 911.
[Full Text]


Home page
JWatch Emergency Med.Home page
Amiodarone Restores and Maintains Sinus Rhythm in CHF Patients with AF
Journal Watch Emergency Medicine, February 1, 1999; 1999(201): 6 - 6.
[Full Text]